Connect
MJA
MJA

Buprenorphine: extended‐release formulations “a game changer”!

Katerina Lagios
Med J Aust 2021; 214 (11): . || doi: 10.5694/mja2.51098
Published online: 21 June 2021

To the Editor: There is a new player in the treatment of opioid use disorder: extended‐release depot buprenorphine. This has been hailed “a game changer”1 and has proven to be of great benefit, particularly during the current coronavirus disease 2019 (COVID‐19) pandemic. Depot buprenorphine has an impact on presentations to hospital and health services, meaning that all clinicians must be familiar with the advantages and disadvantages (Box) as well as the formulations.

  • Katerina Lagios

  • Mental Health, Justice Health and Alcohol and Drug Services, ACT Health, Canberra, ACT

Correspondence: katerina.lagios@act.gov.au

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.